⏳ Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Bioventus exec sells over $6,000 in company stock

Published 15/04/2024, 23:02
BVS
-

In a recent move, Katrina J. Church, the Senior Vice President & Chief Compliance Officer of Bioventus Inc. (NASDAQ:BVS), sold 1,325 shares of the company's stock. The transaction, which took place on April 11, 2024, was part of a prearranged trading plan and was executed to cover tax obligations related to the vesting of restricted stock units.

The shares were sold at a weighted average price of $4.75, totaling approximately $6,293. The price range for these shares varied from $4.53 to $4.95, with the specific distribution of shares sold at each price available upon request. This sale was conducted under a 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for buying or selling stocks at a time when they are not in possession of nonpublic information.

Following the sale, Church's direct ownership in Bioventus Inc. stands at 17,042 shares. The company, which specializes in surgical and medical instruments and apparatus, has its headquarters in Durham, North Carolina.

Investors and followers of Bioventus Inc. will note that insider sales and purchases can be indicative of a company's financial health and executive confidence. Transactions like these are reported to the Securities and Exchange Commission and are publicly accessible for review.

InvestingPro Insights

As Bioventus Inc. (NASDAQ:BVS) navigates through the financial year, the company's performance and executive transactions are of keen interest to investors. According to InvestingPro data, Bioventus has a market capitalization of $366.54 million and has demonstrated significant price volatility, with a 6-month price total return of 80.28% and a staggering 1-year price total return of 391.51%. This reflects a large price uptick that aligns with one of the InvestingPro Tips, suggesting a robust performance in the stock market over the past year.

The company's revenue has seen a modest increase in the last twelve months as of Q4 2023, with a growth of 0.04%, while the quarterly revenue growth for Q4 2023 was more substantial at 7.62%. Despite this, the company has been grappling with profitability, as evidenced by a negative P/E ratio of -1.86, which has adjusted further to -5.53 for the last twelve months as of Q4 2023. This aligns with another InvestingPro Tip indicating that the company has not been profitable over the last twelve months, although analysts predict it will be profitable this year.

For those interested in more in-depth analysis and additional insights, InvestingPro offers further tips on Bioventus Inc., which can be found at https://www.investing.com/pro/BVS. Currently, there are 9 additional InvestingPro Tips available for investors to consider. To gain access to these valuable insights, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.